¼ºÇʼö ¸íÀÇ

ȯÀÚÀÇ Àå±â »ýÁ¸À» À§ÇØ ÃÖ¼±À» ´ÙÇÏ´Â °£¾Ï ¹× °£Áúȯ Àü¹®°¡

¼ºÇʼö ¸íÀÇ

  • ¼Ò ¼Ó
    °¡Å縯´ë¼­¿ï¼º¸ðº´¿ø ¼ÒÈ­±â³»°ú
  • Àü¹®ºÐ¾ß
    °£¾Ï, °£°æº¯, °íÀ§Çè Áö¹æ°£, ÀÚ°¡¸é¿ª°£Áúȯ, °£¿°, °£Á¶Á÷°Ë»ç

ÇöÀç ¼­¿ï¼º¸ðº´¿ø ¼ÒÈ­±â³»°ú ±³¼ö·Î ÀçÁ÷ ÁßÀ̸ç, °¡Å縯ÀÇ´ë ÀǰúÇаú¿Í µðÁöÅÐÇコÇаú¿¡¼­µµ ±³¼ö·Î Ȱµ¿Çϰí ÀÖ´Ù. ´ëÇѼÒÈ­±âÇÐȸ, ´ëÇѰ£ÇÐȸ, ´ëÇѰ£¾ÏÇÐȸ µî¿¡¼­ À§¿øÀ¸·Î Ȱµ¿ÇØ ¿ÔÀ¸¸ç, ÁÖ¿ä ¿¬±¸ ºÐ¾ß´Â ¡ã°£¾ÏÀÇ ¸é¿ª¡¤¼¼Æ÷ Ä¡·á ¡ã°£¿°¡¤°£°æº¯ÀÇ ¿øÀÎ ±Ô¸í°ú Ä¡·á´Ù. ±âÃÊ ¿¬±¸¿¡¼­ ÀÓ»ó Àû¿ë±îÁö Æø³ÐÀº °æÇèÀ» ¹ÙÅÁÀ¸·Î, °£ ÁúȯÀÇ Á¶±â Áø´Ü°ú ¸ÂÃãÇü Ä¡·á Àü·« °³¹ß¿¡ Èû¾²°í ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °¡Å縯ÀÇ´ë ÀÇÇÐ Çлç
  • °¡Å縯ÀÇ´ë ÀÇÇÐ ¼®»ç
  • Çѱ¹°úÇбâ¼ú¿ø (KAIST) ÀÌÇÐ ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ¼­¿ï¼º¸ðº´¿ø ¼ÒÈ­±â³»°ú ±³¼ö
  • ¼­¿ï¼º¸ðº´¿ø ¼ÒÈ­±â³»°ú ºÎ±³¼ö (2022 ~ 2025)
  • ¼­¿ï¼º¸ðº´¿ø ¼ÒÈ­±â³»°ú Á¶±³¼ö (2020 ~ 2022)

¼ö»ó³»¿ª

Awards List
  • °¡Å縯ÀÇ´ë º´¸®ÇÐ ½Ç½À»ó (20004)
  • °¡Å縯´ëÇб³ ÃÑÀå»ó : °¡Å縯ÀÇ´ë 48ȸ ¼ö¼®Á¹ (2007)
  • Çѱ¹º¸°ÇÀÇ·áÀα¹°¡½ÃÇè¿øÀå»ó : 71ȸ Àǻ籹°¡°í½Ã Àü±¹¼ö¼® (2007)
  • °­³²¼º¸ðº´¿ø ¿ì¼öÀÎÅÏ»ó (2007)
  • ³»°úÇб³½Ç ÃÖ¿ì¼öÀü°øÀÇ, Àü°øÀÇ³í¹®»ó, °ø·Î»ó (2009 ~ 2012)
  • ³»°úÇб³½Ç Ưº°°ø·Î»ó : 55ȸ ³»°ú Àü¹®ÀÇ Àü±¹¼ö¼® (2012)
  • Çѱ¹¿¬±¸Àç´Ü ±Û·Î¹ú¹Ú»çÆç·Î¿ì½± ¿¬±¸ºñ ¼öÇý (2012)
  • ´ëÇÑ °£ÇÐȸ ÃÖ¿ì¼ö ³í¹®»ó (2012, 2018)
  • ¹Ì±¹°£ÇÐȸ ¿ì¼ö Æ÷½ºÅÍ»ó (2013, 2020, 2024)
  • ¾Æ½Ã¾ÆÅÂÆò¾ç °£ÇÐȸ ¿ì¼ö ±¸¿¬»ó (2015, 2017)
  • ¼­¿ï¼º¸ðº´¿ø °³ÀαâÃÊ¿¬±¸ºñ(2016)
  • KAIST »ý¸í°úÇбâ¼ú´ëÇÐ ¿ì¼ö ¹Ú»çÇÐÀ§ ³í¹®»ó (2016)
  • °ú±âºÎ Çѱ¹¿¬±¸Àç´Ü À̰øÇа³ÀαâÃÊ¿¬±¸ ¿¬±¸ºñ ¼öÇý (2017)
  • ¼¼°è°£¾ÏÇÐȸ ÀþÀº¿¬±¸ÀÚ»ó (2017)
  • ¼­¿ï¼º¸ðº´¿ø ±â¼ú»ç¾÷È­¿¬±¸ºñ (2018, 2020)
  • 2020 ±³À°ºÎ ¿ì¼ö¿¬±¸¼º°ú 50¼± ¼±Á¤ (2021)
  • ´ëÇѰ£¾ÏÇÐȸ Çмú»ó : ±âÃÊÁß°³¿¬±¸ (2021)
  • °ú±âºÎ Çѱ¹¿¬±¸Àç´Ü À̰øÇа³ÀαâÃÊ¿¬±¸ ¿¬±¸ºñ ¼öÇý : ¿ì¼ö½ÅÁø (2021)
  • ´ëÇÑ °£ÇÐȸ ¿ì¼ö ±¸¿¬»ó (2013, 2015, 2016, 2017, 2019, 2020, 2022, 2023, 2024)
  • ´ëÇѰ£¾ÏÇÐȸ ÃÖ¿ì¼ö±¸¿¬»ó (2019, 2023)
  • ±³À°ºÎ Çѱ¹¿¬±¸Àç´Ü À̰øÇа³ÀαâÃÊ¿¬±¸ ¿¬±¸ºñ ¼öÇý (2019)
  • °¡Å縯ÀÇ´ë ³»°úÇб³½Ç Çмú¿¬±¸ºñ ¼öÇý (2019)
  • ´ë¿õÁ¦¾à Çмú¿¬±¸ºñ ¼öÇý (2020)
  • °¡Å縯ÀÇ´ë Ãѵ¿¹®È¸ Çмú¿¬±¸ºñ ¼öÇý (2020)
  • ¼­¿ï¼º¸ðº´¿ø ¸®´õ¿¬±¸ÀÚ ¿¬±¸ºñ ¼öÇý (2022)
  • ¾Æ½Ã¾ÆÅÂÆò¾ç °£ÇÐȸ presidential award (2023)
  • "Gut and Liver" best reviewer (2023)
  • KDDW contribution award (2022, 2023, 2024)
  • clinical and molecular hepatology ÃÖ´ÙÀοë»ó (2024)

ÇÐȸȰµ¿

Academic activities
  • ´ëÇѼÒÈ­±âÇÐȸ ¿¬±¸±âȹÀ§¿ø
  • ´ëÇѰ£ÇÐȸ °£ÇàÀ§¿ø
  • ´ëÇѰ£¾ÏÇÐȸ ÇмúÀ§¿ø
  • ´ëÇѰ£¾ÏÇÐȸ °£ÇàÀ§¿ø
  • Áö¹æ°£¿¬±¸È¸ ÇмúÀ§¿ø
  • ´ëÇѰ£¾ÏÇÐȸ ¿¬±¸À§¿ø(°£»ç)
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Immune responses and immunopathology in acute and chronic viral hepatitis
¹ßÇ¥³âµµ 2016 ¹ßÇ¥Áö Nature Reviews Immunology.
Á¦ ¸ñ Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Hepatology
Á¦ ¸ñ Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Clinical and molecular hepatology
Á¦ ¸ñ Intrahepatic inflammatory IgA + PD-L1 high monocytes in hepatocellular carcinoma development and immunotherapy
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Journal for Immunotherapy of cancer
Á¦ ¸ñ Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö Liver cancer
Á¦ ¸ñ EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö Journal for Immunotherapy of cancer
Á¦ ¸ñ Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Biomedicine and pharmacotherapy

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

°£¾ÏÀÇ ´ÙÇÐÁ¦Àû Ä¡·á ¹× ¸é¿ªÇ×¾ÏÄ¡·á¿Í °£Áúȯ ¸é¿ªÇÐ ºÐ¾ß¿¡ °¡Àå ±íÀº °ü½É°ú Àü¹®¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÓ»ó ¿¬±¸ »Ó ¾Æ´Ï¶ó ±âÃÊ ¿¬±¸¿¡¼­µµ µÎ°¢À» ³ªÅ¸³»°í Àִµ¥, ÃÖ±Ù ¿¬±¸´Â °£¾ÏÀÇ ¸é¿ª Á¶Àý ±âÀü°ú ¸é¿ª ȸº¹À» ÅëÇÑ Ä¡·á Àü·« °³¹ß¿¡ ÃÊÁ¡ÀÌ ¸ÂÃß¾îÁ® ÀÖ½À´Ï´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

ȯÀÚ Áø·á¿¡¼­ Áúº´ÀÇ Ä¡·á»Ó ¾Æ´Ï¶ó ±âÀú ÁúȯÀÇ °ü¸®¿Í »îÀÇ Áú Çâ»óÀ» µ¿½Ã¿¡ ´Þ¼ºÇÒ ¼ö ÀÖ´Â Àü·«À» µµÃâÇÏ´Â °ÍÀ» °¡Àå Áß¿äÇÏ°Ô ¿©±ä´Ù. ´Ü¼øÈ÷ °Ë»ç °á°ú³ª ¿µ»ó ¼Ò°ß¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í, ȯÀÚÀÇ º´·Â¡¤»ýȰ½À°ü¡¤½É¸®Àû ¹è°æ±îÁö Á¾ÇÕÀûÀ¸·Î °í·ÁÇÏ¿© ¸ÂÃãÇü Áø´Ü°ú Ä¡·á¸¦ Ãß±¸ÇÑ´Ù. ¶ÇÇÑ ±Ù°Å Á᫐ ÀÇÇÐ(Evidence-based medicine) ¿¡ ±â¹ÝÇϵÇ, ÀÓ»óÀÇÀÇ °æÇè°ú Á÷°üÀ» Á¶È­½ÃŰ´Â °ÍÀ» ÇÙ½É °¡Ä¡·Î »ï°í ÀÖ´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

¹«¾ùº¸´Ù Àú´Â ¾î¶² »óȲ¿¡¼­µµ ȯÀÚ¸¦ ³¡±îÁö, Àý´ë·Î Æ÷±âÇÏÁö ¾Ê°Ú½À´Ï´Ù. ¶ÇÇÑ Àú´Â ȯÀÚÀÇ º´¸¸ÀÌ ¾Æ´Ï¶ó »î Àüü¸¦ ÇÔ²² µ¹º¸´Â Àǻ簡 µÇ°íÀÚ ÇÕ´Ï´Ù. º´ÀÇ ¿øÀΰú Ä¡·á, ±×¸®°í ±× µÚ¿¡ Àִ ȯÀÚÀÇ »ýȰ°ú ¸¶À½±îÁö »ìÇÇ¸ç ´õ ³ªÀº »îÀÇ ÁúÀ» ¸¸µé¾î °¡°Ú½À´Ï´Ù. °úÇÐÀû ±Ù°Å¿Í ÀÓ»ó °æÇèÀ» ¹ÙÅÁÀ¸·Î, ȯÀÚ ÇÑ ºÐ ÇÑ ºÐ¿¡°Ô °¡Àå ÀûÇÕÇÑ ±æÀ» ÇÔ²² ã¾Æ°¡°Ú½À´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°¡Å縯´ë¼­¿ï¼º¸ðº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-1511
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°¡Å縯´ë¼­¿ï¼º¸ðº´¿øÀº 1980³â °­³² Áö¿ª ÃÖÃÊÀÇ Á¾ÇÕº´¿øÀ¸·Î ¼¼¿öÁ³´Ù. ÇöÀç Áö»ó 22Ãþ, ÁöÇÏ 6ÃþÀÇ 1355º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖÀ¸¸ç ´ÜÀÏ °Ç¹° º´¿øÀ¸·Î´Â ±¹³» ÃÖ´ë ±Ô¸ðÀÌ´Ù. °¡Å縯´ë¼­¿ï¼º¸ðº´¿øÀº °¡Å縯±³È¸ÀÇ ´ëÇ¥ º´¿øÀ¸·Î °¡Å縯Áß¾ÓÀÇ·á¿øÀÇ ÀÌ³ä ½Çõ¿¡ Àû±Ø ¾ÕÀå¼­°í ÀÖÀ¸¸ç, ȯÀÚ¸¦ ¸ÕÀú »ý°¢ÇÏ´Â Àü¹®¼¾ÅÍ Áß½ÉÀÇ º´¿ø, 21¼¼±â ÃÖ÷´Ü ÀÇ·á ½Ã½ºÅÛ º´¿øÀ¸·Î °Åµì³ª°í ÀÖ´Ù.

°¡Å縯´ë¼­¿ï¼º¸ðº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ¼­Ãʱ¸ ¹ÝÆ÷´ë·Î 222

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä